Market Moves

Synchron's Neural Data Ambitions Earn Fast Company Recognition as BCI Dataset Grows

Synchron was named the eighth most innovative data science company of 2026 by Fast Company, a ranking that reflects the company’s positioning as a neural data platform rather than a pure medical device maker.

The recognition follows a year in which Synchron’s U.S. COMMAND study moved from clinical feasibility to home-use validation. Patients used the Stentrode, a brain-computer interface implanted through blood vessels without open brain surgery, to control digital devices, send text messages, and compose emails from home. The study produced what the company describes as the largest United States dataset ever generated by an implanted BCI, built on more than twenty patient-years of continuously recorded brain activity.

That dataset underpins Chiral, a cognitive AI foundation model whose roadmap Synchron unveiled with Nvidia at GTC in 2025. Chiral trains on self-supervised neural data, learning directly from how the brain encodes intention rather than relying on labelled training sets. As more patients use the Stentrode for longer periods, the model improves, creating a feedback loop between hardware deployment and software capability.

Fast Company’s placement of Synchron in the data science category rather than the medical device or computing category signals how the company wants to be understood. The BCI itself is the data collection instrument; the long-term commercial value, in Synchron’s framing, sits in the neural data and the models trained on it. The question is whether that data moat proves defensible. Other BCI companies, including Neuralink and Blackrock Neurotech, are accumulating their own neural recordings as their trial cohorts grow. The difference so far is that Synchron has been the most explicit about treating the data as a product layer, not just a research byproduct.

The company has raised US$345 million in total, including a US$200 million Series D in November 2025, and its first-generation Stentrode has been implanted in ten patients in clinical trials in the United States and Australia. The endovascular approach avoids open brain surgery. In those early studies, no participant had a device-related serious adverse event that led to death or permanent increased disability within a year.

Whether the neural data platform model translates into revenue remains to be seen. Foundation models require scale, and twenty patient-years of data is substantial for the BCI field but modest by the standards of AI training generally. Synchron’s bet is that neural data is scarce enough and hard enough to collect that even a relatively small dataset confers a meaningful advantage, provided the company can maintain its lead in patient enrolment and continuous recording time.

Correction, 13 November 2026: An earlier version of this article said Synchron had implanted its Stentrode in more than fifty patients, had raised over $200 million and had no serious adverse events reported to date. Synchron’s November 2025 Series D announcement put the number of patients implanted at ten and total funding at US$345 million, and the safety sentence now matches the published trial results. The description of Chiral has also been clarified.

Weekly BCI Brief in your inbox

Join researchers, investors, and industry leaders who start their day with Inside BCI.